Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPOXYPHENE HYDROCHLORIDE 65 vs DARVON-N
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Propoxyphene is a centrally acting opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting pain signal transmission and altering pain perception. It also has local anesthetic effects.
Propoxyphene is a weak mu-opioid receptor agonist that produces analgesia by binding to opioid receptors in the central nervous system, altering the perception of and response to pain. Its metabolite norpropoxyphene has local anesthetic and sodium channel blocking effects, which may contribute to cardiac toxicity.
Mild to moderate pain (FDA approved)
Mild to moderate pain,Off-label: None established
65 mg orally every 4 hours as needed for pain; maximum 390 mg/day.
100 mg orally every 4 hours as needed for pain; maximum 600 mg per day.
6-12 hours (mean ~8 hours); prolonged in hepatic impairment and elderly; accumulation possible with repeated dosing.
Propoxyphene: 6-12 hours; norpropoxyphene: 30-36 hours. Accumulation of norpropoxyphene on repeated dosing increases risk of toxicity.
Primarily hepatic via N-demethylation (CYP3A4) to norpropoxyphene, an active metabolite with longer half-life and potential for toxicity.
GFR 10-50 m L/min: administer 50% of normal dose every 6 hours. GFR <10 m L/min: administer 50% of normal dose every 6-8 hours or avoid use; increase risk of accumulation of toxic metabolite norpropoxyphene.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: reduce dose by 50% or extend interval to every 8-12 hours; not recommended for GFR <15 m L/min.
Propoxyphene is associated with a risk of fatal respiratory depression, especially when used in higher doses, in elderly patients, or in combination with other CNS depressants. It increases the risk of QT prolongation and fatal arrhythmias, leading to its withdrawal from the market in some countries.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with neonatal respiratory depression, withdrawal syndrome if chronic use near term. Avoid prolonged use.
First trimester: Limited data; potential for neural tube defects with first-trimester exposure. Second and third trimesters: Risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal withdrawal syndrome. Use only if clearly needed.
Propoxyphene is a weak opioid with efficacy similar to aspirin but carries a high risk of QT prolongation and cardiotoxicity, especially in overdose or with renal impairment. Avoid in patients with history of QT prolongation, electrolyte disturbances, or concurrent use of other QT-prolonging drugs. Due to its narrow therapeutic index and risk of fatal arrhythmias, it has been withdrawn from many markets. Use with extreme caution in elderly and those with hepatic/renal dysfunction.
Darvon-N (propoxyphene napsylate) is a weak opioid analgesic with efficacy similar to codeine; its use is limited by narrow therapeutic index and risk of QT prolongation. It is metabolized by CYP2D6 to norpropoxyphene, which has a long half-life and can accumulate, causing CNS toxicity. Due to safety concerns, it has been withdrawn from many markets; avoid in patients with substance use disorder, renal impairment, or those taking CNS depressants. Monitor for QTc prolongation if used with other QT-prolonging agents.
No interactions on record
No interactions on record
PROPOXYPHENE HYDROCHLORIDE 65 and DARVON-N are distinct pharmacological agents. PROPOXYPHENE HYDROCHLORIDE 65 belongs to the Opioid Analgesic class and is primarily used for Mild to moderate pain (FDA approved). DARVON-N belongs to the Opioid Analgesic class and is primarily used for Mild to moderate painOff-label: None established. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. PROPOXYPHENE HYDROCHLORIDE 65 carries a safety status of Category C, whereas DARVON-N safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily hepatic via CYP3A4 and CYP2D6 to norpropoxyphene (active metabolite). Propoxyphene and norpropoxyphene undergo further metabolism and conjugation.
Renal excretion of unchanged drug (approximately 20-30%) and metabolites; approximately 40-60% as conjugated metabolites; minor biliary/fecal elimination.
Primarily renal (approximately 70% as unchanged drug and glucuronide conjugates); minor biliary/fecal elimination (25-30%).
40-50% bound to albumin and alpha-1-acid glycoprotein.
Propoxyphene: 70-80%; norpropoxyphene: 75-85%. Primarily bound to albumin.
8-16 L/kg; extensive tissue distribution, including CNS.
Propoxyphene: 12-26 L/kg; widely distributed into tissues, including CNS.
Oral: 30-70% due to first-pass metabolism.
Oral: approximately 30-70% due to extensive first-pass metabolism; interindividual variability.
Child-Pugh Class A and B: reduce dose by 50% and extend dosing interval to every 6-8 hours. Child-Pugh Class C: contraindicated due to risk of accumulation and toxicity; alternative therapy recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Not recommended for use in children due to risk of respiratory depression and toxicity. No established weight-based dosing guidelines.
Not recommended for children under 12 years; for adolescents 12-17 years: 100 mg every 4 hours as needed, maximum 400 mg per day.
Initiate at 50% of adult dose (e.g., 32.5 mg) every 6 hours as needed; cautiously titrate due to prolonged half-life, increased CNS sensitivity, and risk of falls. Avoid use if possible; alternative safer analgesics recommended.
Initiate at 50 mg every 4 hours as needed; maximum 400 mg per day; monitor for CNS depression and constipation.
DARVON-N (propoxyphene) is contraindicated in patients with a history of drug abuse, and its use should be monitored for signs of abuse, addiction, or misuse. It should not be used in patients with severe respiratory depression, acute or severe bronchial asthma, or known hypersensitivity to propoxyphene. Additionally, because of the risk of QT prolongation and cardiac arrhythmias, propoxyphene-containing products were withdrawn from the US market in 2010.
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression and hepatotoxicity risk; grapefruit juice may inhibit metabolism and increase propoxyphene levels.
Avoid alcohol; may enhance CNS depression. No specific food interactions known, but high-fat meals may delay absorption.
Excreted in breast milk; M/P ratio 0.27. Use with caution; monitor infant for sedation, respiratory depression. Consider alternative analgesia.
Propoxyphene is excreted into breast milk with a milk-to-plasma ratio of approximately 1.0. Theoretical risk of neonatal respiratory depression and withdrawal. Not recommended; consider alternative analgesics.
Decreased clearance in pregnancy may require dose reduction; avoid supratherapeutic doses; taper if discontinuing to prevent withdrawal.
Increased clearance in pregnancy may necessitate higher doses; however, due to risks, avoid use or limit to lowest effective dose for shortest duration. No established dose adjustment guidelines.
Take exactly as prescribed; do not increase dose or frequency.,Do not consume alcohol or other CNS depressants while taking this medication.,Do not drive or operate heavy machinery until you know how this drug affects you.,Seek immediate medical attention if you experience fainting, irregular heartbeat, or seizures.,Do not stop abruptly without consulting your doctor; withdrawal symptoms may occur.,Keep out of reach of children; accidental overdose can be fatal.
Take exactly as prescribed; do not increase dose or frequency due to risk of serious side effects including seizures and cardiac arrhythmias.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of respiratory depression and sedation.,Do not stop abruptly after prolonged use; withdrawal symptoms may occur.,Store securely out of reach of children; dispose of unused medication properly.,Use caution when driving or operating machinery; may cause dizziness or drowsiness.,Report new or worsening shortness of breath, irregular heartbeat, or fainting to your healthcare provider.